Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07921797

Long-Term Performance of Kingstron X-LINK Compared With Commercial Bioprostheses

Conditions: AORTIC VALVE DISEASES, Mitral Valve Disease

Sex: All
Healthy volunteers: No
Enrollment: 268
Sponsor: West China Hospital

Summary

The goal of this prospective cohort study is to evaluate the long term clinical performance of the Kingstron X LINK bioprosthesis for aortic or mitral valve replacement, and verify whether its postoperative outcomes are non inferior to commercially available Medtronic Mosaic and Edwards Perimount Magna bioprostheses. It will also assess safety, hemodynamic performance and patient quality of life after valve implantation. The main questions it aims to answer are: Does the Kingstron X LINK bioprosthesis yield non inferior long term overall survival compared with Medtronic and Edwards bioprostheses? What are the differences in structural valve degeneration, adverse events, reoperation free survival and hemodynamic outcomes between the Kingstron X LINK and the comparator bioprostheses? How does patient quality of life differ across the three bioprosthesis groups during long term follow up? Researchers will compare patients receiving Kingstron X LINK bioprostheses against those receiving Medtronic Mosaic or Edwards Perimount Magna bioprostheses, all of whom underwent surgical aortic and/or mitral valve replacement at West China Hospital. Participants will: Receive surgical aortic valve replacement and/or mitral valve replacement with one of the three types of bioprosthetic valves. Complete annual clinical follow up including clinical examination, hemodynamic assessment and quality of life evaluation. Be monitored for adverse events, structural valve degeneration and reoperation events over long term follow up.

Eligibility Criteria

Inclusion Criteria: \- (1) Adults scheduled to undergo or undergoing primary surgical AVR with either a Kingstron X-LINK, Medtronic Mosaic, or Edwards Perimount Magna bioprosthesis between November 2015 and August 2018. (2) Adults scheduled to undergo or undergoing primary surgical MVR with a Kingstron X-LINK, Medtronic Mosaic, or Edwards Perimount Magna bioprosthesis during the same interval. Exclusion Criteria: * (1) Patients with active or suspected infective endocarditis at the time of valve surgery were excluded. (2) Patients who had previously undergone cardiac valve replacement surgery were excluded. (3) Patients who declined or were unable to provide written informed consent for study participation and annual follow-up were excluded.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07921797). StuddyBuddy aggregates publicly available trial information.